Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) has scheduled its Q4 and full-year 2024 financial results conference call and webcast for March 11, 2025, at 4:30 p.m. ET. The dermatology therapeutics company will present financial performance data and provide a corporate update during the event.

Participants can join via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) using conference ID: VERRICA. The webcast will be accessible through the company's investor relations website section, with a replay available for 90 days post-event.

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update.

Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts, one of the largest remaining unmet needs in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com

FAQ

When will Verrica Pharmaceuticals (VRCA) release its Q4 and full-year 2024 earnings?

Verrica Pharmaceuticals will release its Q4 and full-year 2024 earnings on March 11, 2025, at 4:30 p.m. ET.

How can investors access Verrica Pharmaceuticals' (VRCA) Q4 2024 earnings call?

Investors can dial 1-800-445-7795 (domestic) or 1-785-424-1699 (international) using ID: VERRICA, or access the webcast through Verrica's website.

How long will VRCA's Q4 2024 earnings webcast replay be available?

The webcast replay will be archived on Verrica's website for 90 days following the event.

What topics will be covered in Verrica Pharmaceuticals' (VRCA) upcoming earnings call?

The call will cover Q4 and full-year 2024 financial results and provide a corporate update.